Cytosystems Secures Horizon Grant of €3.2 million
Grant Will Be Used to Accelerate Commercialisation of Bladder Cancer Diagnostic
Aberdeen, 4 May 2016 … Cytosystems, a clinical stage diagnostic company, developing new diagnostics for bladder and prostate cancer, has been awarded a grant of €3.2 million, through the EU Horizon 2020 Scheme, one of the largest grants to be awarded to the life sciences sector of the UK, and the largest for Scotland.
Cytosystems has developed a range of technologies which can be used to improve the diagnosis and management of bladder cancer. The grant will be used to validate specific biomarkers, found in urine, which can be used to accurately detect the presence of cancer.
The grant will allow Cytosystems to fast track development of a non-invasive in-vitro diagnostic, providing end users and purchasing decision makers with the tests accuracy and health economic benefit through completion of a multi-centre clinical trial.
Cytosystems has developed a novel technology for urine cytology called BladderLight™, which will be clinically validated through this grant. BladderLight™ is a novel diagnostic technology that enables a diagnosis with improved accuracy that is non-invasive. This technology provides physicians with the tools for collecting and processing the patients’ urine, testing the urine for the presence of cancer cells, rather than the traditional method of cystoscopy, an uncomfortable and invasive test.
Not only will BladderLightTM aid the initial diagnosis of bladder cancer, the test will also relieve some of the burden of the management of bladder cancer post-treatment. Bladder cancer patients, due to the high recurrence of the disease, need frequent surveillance post treatment – up to four times per year in the first two years, then reducing to biannually, and annually after five years.
In particular, the grant will see the final validation of the MCM2 biomarker together with the company’s proprietary urine processing device and digital analysis system, in a multi-centred clinical trial within UK, EU and USA hospitals. The grant provides Cytosystems with the resources to gain a CE Mark and FDA approval for BladderLight™.
Richard Berry, CEO of Cytosystems, said: “This grant will allow the company to fully validate its technologies, and prepare for full commercialisation. Having already completed a number of trials where we have demonstrated the clinical efficacy of the BladderLightTM test, this grant will allow us to take the company forward and fully exploit the available commercial opportunities.”
Dr. Nigel McLean, Director of Product Management from Cytosystems, added: “A wealth of previous studies has highlighted the benefits of our technology. Not only can it improve diagnosis and ultimately patient care, but is also far less invasive for patients. In addition, we believe there are significant cost benefits associated with the adoption of our technologies for the surveillance of patients having received treatment for bladder cancer.”
For further information, please contact:
Tel: +44 (0)7899 796655
Notes to Editors: Cytosystems is a clinical stage diagnostic development company, currently focussed on the development of technology for the diagnosis and management of urological cancers such as bladder and prostate cancer. The company has developed a novel technology for urine cytology called BladderLight™, that enables a diagnosis with very high accuracy, that is non-invasive thus more acceptable to patients than the current invasive procedure. Cytosystems was established in 2006, and has been developing new diagnostic technologies that not only improve diagnosis and management of bladder cancer, but are also more acceptable to patients, by being less intrusive. www.cytosystems.com